Quantcast

Latest diabetic macular edema Stories

2014-08-20 08:27:26

SOUTHAMPTON, England, August 20, 2014 /PRNewswire/ -- Phase I Trial of Plasma Kallikrein Inhibitor to be Conducted in the US KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. The study's Principal Investigator is Dr. Jennifer K Sun of the Beetham Eye Institute, Joslin...

2014-08-11 04:21:54

TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema (DME). Bayer Healthcare plans to launch EYLEA in DME in the EU this quarter. "DME is the leading cause of vision loss in working-age adults in much of the developed world, and we believe EYLEA will be an important new treatment...

2014-07-29 20:23:16

DME is the third approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA(®) (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of EYLEA in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. Although EYLEA may be dosed as...

2014-07-14 23:03:57

The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for diabetic macular edema (DME) patients. Hicksville and Hauppauge, NY (PRWEB) July 14, 2014 The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for...

2014-06-27 08:24:46

TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to diabetic macular edema (DME). The decision of the European Commission is expected in the second half of 2014. "Diabetes is a growing health concern worldwide and this milestone brings us...

2014-06-09 08:29:08

VANCOUVER, June 9, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced top-line results related to the eight month visual acuity (VA) primary endpoint for subjects enrolled in the Phase 2 iDEAL Study, conducted in collaboration with JDRF, evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). Statistical methods employed included both Last Observation Carry...

2014-04-29 08:34:38

VANCOUVER, April 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today announced that research collaborators will make a poster presentation at the Association for Research in Vision and Ophthalmology 2014 Annual Meeting. The Meeting is being held from May 4(th) - 8(th), 2014 in Orlando, Florida. "The data being presented outlines patient demographics and baseline characteristics of each arm of the phase two iDEAL study, as well as...

2014-04-24 16:29:47

VANCOUVER, April 24, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the year ended December 31, 2013. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). "Our team, working with world-class retinal experts, was extremely pleased with 2013 clinical progress," said Andrew Rae, President & CEO of iCo...

2014-03-10 04:21:04

LEUVEN, Belgium, March 10, 2014 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a EUR3 million grant from the Flemish agency for Innovation by Science and Technology (IWT). The grant funding will be used by ThromboGenics to support research into potential new biotherapeutics for the...

2014-03-05 08:28:36

VANCOUVER, March 5, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related